This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Medfield Pharmaceuticals - Teaching Note
Lipson, Marc L.; Harris, Jared D.Teaching Note DARDEN-F-1636TN-EFinanceTeaching note for product F-1636Starting at €0.00
-
Silic (B): Choosing Cost or Fair Value on Adoption of IFRS
Hawkins, David F.; Dessain, Vincent; Barron, AndrewCase HBS-108031-EAccounting and ControlSupplements the (A) case.Starting at €5.74
-
Silic (A): Choosing Cost or Fair Value on Adoption of IFRS
Hawkins, David F.; Dessain, Vincent; Barron, AndrewCase HBS-108030-EAccounting and ControlA French real estate firm must choose to report its primary asset (investment property) using either cost or fair-value accounting methods upon adoption of international accounting standards (IAS) in 2005.Starting at €8.20
-
Medfield Pharmaceuticals
Lipson, Marc L.; Mead, Jenny; Harris, Jared D.Case DARDEN-F-1636-EFinanceSusan Johnson, founder and CEO of Medfield Pharmaceuticals, is faced with conflicting recommendations for extending the patent life of the company’s flagship product, Fleximat, scheduled to go off patent in two years. With only three other products in Medfield’s lineup of medications, one of which has only just received U.S. Food and Drug Administration approval, strategic management of the company’s product pipeline is of paramount importance. B...Starting at €8.20
-
Silic (A) and (B): Choosing Cost or Fair Value on Adoption of IFRS, Teaching Note
Dessain, Vincent; Barron, Andrew; Hawkins, David F.; Riedl, Edward J.Teaching Note HBS-108078-EAccounting and ControlTeaching Note for 108-030 and 108-031.Starting at €0.00